Your Health and Fitness Partner: Androxal & FitHub

We are also excited to expand our scope by including valuable information on Androxal, a potent medication beneficial in various medical conditions. This remarkable drug, derived from the testosterone molecule, has made its mark significantly in the field of endocrinology. Patients and medical professionals can rely on our comprehensive, unbiased, and scientifically grounded content on Androxal for gaining a robust understanding of its uses, side effects, and the latest studies related to it. We understand the necessity of accurate information when it comes to medication. Our newly launched section dedicated to Androxal aims at not only educating the readers about its nuances but also at contributing beneficially to their wellbeing. Stay tuned for insightful articles unraveling the potential of Androxal in medical science.

Sitemap | Policies | Feedback    
 About the Journal
Editorial Board
Journal Subscription
Instructions for Authors
E-mail Alerts
Forthcoming Events
Advertise with Us
Contact Us
 
Article Options
FULL TEXT
ABSTRACT
PDF
Printer Friendly Version
Search Pubmed for
Search Google Scholar for
Article Statistics
Bookmark and Share
 
Hepatopulmonary syndrome: prevalence and predictors in Egyptian cirrhotic patients
 
Mona A. Abu El Makarem,1 Atef Elakad,1 Ahmed Ali,1 Mohammed Abd-Elkader,2 Azza Farag Sayed,3 Amira Taha,1 Tarek Abd-Elrhman2
Department of Internal Medicine,1
Department of Cardiology,2
Department of Chest,3
Medical School, Minia University and
Department of Internal Medicine4
Medical School, Beni-Suif University
Egypt.


Corresponding Author
: Dr. Mona Abu El Makarem
Email: mona.makarem@yahoo.com


Abstract

Background: The reported prevalence of hepatopulmonary syndrome (HPS) in cirrhotic patients is heterogeneous. Although the prevalence of chronic liver diseases is high in Egypt, however, scanty data is available about HPS.

 

Aim: To assess the frequency of HPS and factors predictive of diagnosis of HPS in Egyptian patients with liver cirrhosis.

 

Methods: Fifty cirrhotic patients were evaluated for the presence of HPS. Orthodeoxia was measured by arterial blood gas test. The patients positive for diagnostic criteria of HPS (the presence of A–a O2 > 15 mmHg and pulmonary vascular dilatation assessed by contrast enhanced echocardiography) were defined as clinical HPS cases and those manifesting with intrapulmonary arterial dilation but no other criteria were defined as subclinical HPS cases.

 

 Results: Subclinical HPS and clinical HPS was observed in 10 (20%) and 17 (34%) of the patients, respectively. The presence of HPS was significantly associated with severity of liver disease assessed by the Child-Pugh score (CP) or MELD score. Portal vein diameter (mm) (OR 3.3; 95% C.I 1.3-8.2; p=0.01) was the only independent predictor for HPS; the specificity of orthodeoxia for diagnosis of HPS was 100%.

 

Conclusions: HPS and intrapulmonary vein dilation are relatively frequent in patients with liver cirrhosis and occur in 34% and 20% of cirrhosis patients, respectively. They are associated with disease severity according to the MELD and CP score. Alveolar arterial oxygen gradient is the most valuable negative and positive diagnostic predictor for presence of HPS in cirrhotic patients.